Breaking News: Imunon (NASDAQ:IMNN) Stock Soars After Positive Phase 2 Clinical Trial Results
Imunon stock is surging today following the release of data from a Phase 2 clinical trial of IMNN-001, the company’s treatment candidate for advanced ovarian cancer. The results showed an 11.1-month increase in overall survival for newly diagnosed patients, with a 35% improvement in survival rate indicated by a hazard ratio of 0.74 in the intent-to-treat population.
Stacy Lindborg, Ph.D., Imunon’s president and CEO, expressed optimism about the results, hinting at the potential for IMNN-001 to improve outcomes for women with advanced ovarian cancer. The company plans to move forward with a Phase 3 pivotal study.
This positive news has led to heavy trading of IMNN shares, with over 36 million shares changing hands compared to the daily average of 103,000 shares. As a result, IMNN stock has surged by 258.5% this morning.
For investors looking for more market insights, our coverage includes updates on Ekso Bionics (NASDAQ:EKSO), QXO (NASDAQ:QXO), and Enveric Biosciences (NASDAQ:ENVB) stocks.
In summary, the successful Phase 2 trial results for IMNN-001 have sparked a massive rally in Imunon stock, signaling promising potential for the company’s treatment in the fight against advanced ovarian cancer. Investors should keep a close eye on further developments as Imunon progresses to the next phase of clinical trials.